News and Media

Eradivir’s EV25 Shows Promising Results in Phase 2a Trial

for the Treatment of Influenza

Eradivir Inc., a clinical-stage biotechnology company that targets the power of the immune system to treat disease, today announced the successful completion of its Phase 2a clinical trial for EV25, a therapy for the treatment of influenza. The study demonstrated that EV25 is safe, well-tolerated and significantly reduces viral loads and influenza symptoms, paving the way for a larger Phase 2b trial. 

Eradivir Secures $10 Million in Private Financing

Eradivir Inc., a clinical-stage biotechnology company that harnesses the power of the immune system to target and treat disease, today announced the recent closing of a $10 million private financing round.

Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza

Challenge study follows Phase 1 study that found EV25 is well tolerated in humans

Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies

Research has been published in Proceedings of the National Academy of Sciences

Interview with Imrul Shahria of Eradivir

Imrul Shahria reckoned there are all kinds of antibodies and immune cells floating through our tissues not doing much, but that could be tricked into tackling flu infections – with a little molecular deception. He's effectively hacked the flu antiviral zanamivir which locks onto the neuraminidase protein – the N – of flu viruses, and given it immune superpowers.

Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a study of influenza therapeutic

Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.

Biotech company Eradivir is developing lead drug EV25 to treat influenza

Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low’s lab at Purdue University to focus on a platform of immunotherapies for viral infections like influenza and other diseases.